Alnylam Pharmaceuticals, Inc. (ALNY) Given Buy Rating at Piper Jaffray Companies

Piper Jaffray Companies reiterated their buy rating on shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in a report published on Friday morning. They currently have a $182.00 price target on the biopharmaceutical company’s stock.

Other analysts have also issued research reports about the stock. Needham & Company LLC reissued a buy rating and issued a $85.00 price target (down previously from $98.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 7th. Jefferies Group LLC set a $102.00 price target on shares of Alnylam Pharmaceuticals and gave the company a buy rating in a research report on Friday, August 25th. BidaskClub lowered shares of Alnylam Pharmaceuticals from a strong-buy rating to a buy rating in a research report on Wednesday, August 16th. Credit Suisse Group reissued a buy rating and issued a $96.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, August 11th. Finally, Stifel Nicolaus reissued a buy rating and issued a $56.00 price target (up previously from $47.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, August 10th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and seventeen have assigned a buy rating to the company. Alnylam Pharmaceuticals currently has an average rating of Buy and an average target price of $121.85.

Alnylam Pharmaceuticals (ALNY) traded up $1.13 during midday trading on Friday, hitting $127.51. 894,411 shares of the stock traded hands, compared to its average volume of 1,135,227. Alnylam Pharmaceuticals has a one year low of $35.98 and a one year high of $147.63. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The business had revenue of $17.10 million during the quarter, compared to the consensus estimate of $28.15 million. During the same period last year, the firm earned ($1.21) EPS. The business’s revenue for the quarter was up 24.8% on a year-over-year basis. research analysts predict that Alnylam Pharmaceuticals will post -5.33 earnings per share for the current fiscal year.

WARNING: “Alnylam Pharmaceuticals, Inc. (ALNY) Given Buy Rating at Piper Jaffray Companies” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://ledgergazette.com/2017/11/18/alnylam-pharmaceuticals-inc-alny-given-buy-rating-at-piper-jaffray-companies.html.

In other news, CEO John Maraganore sold 74,000 shares of the company’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $126.86, for a total value of $9,387,640.00. Following the completion of the sale, the chief executive officer now owns 223,710 shares of the company’s stock, valued at approximately $28,379,850.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Dennis A. Ausiello sold 20,000 shares of the company’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $130.00, for a total transaction of $2,600,000.00. Following the completion of the sale, the director now directly owns 20,000 shares of the company’s stock, valued at approximately $2,600,000. The disclosure for this sale can be found here. Insiders sold a total of 289,797 shares of company stock valued at $34,422,712 in the last ninety days. 4.30% of the stock is owned by corporate insiders.

Several institutional investors have recently made changes to their positions in the company. State of Wisconsin Investment Board boosted its position in Alnylam Pharmaceuticals by 0.7% during the 2nd quarter. State of Wisconsin Investment Board now owns 15,012 shares of the biopharmaceutical company’s stock valued at $1,197,000 after buying an additional 100 shares during the period. The Manufacturers Life Insurance Company boosted its position in Alnylam Pharmaceuticals by 7.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 167 shares during the period. Prudential Financial Inc. boosted its position in Alnylam Pharmaceuticals by 4.8% during the 2nd quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 200 shares during the period. Utah Retirement Systems boosted its position in Alnylam Pharmaceuticals by 1.5% during the 2nd quarter. Utah Retirement Systems now owns 13,800 shares of the biopharmaceutical company’s stock valued at $1,100,000 after buying an additional 200 shares during the period. Finally, Alliancebernstein L.P. boosted its position in Alnylam Pharmaceuticals by 0.8% during the 2nd quarter. Alliancebernstein L.P. now owns 47,873 shares of the biopharmaceutical company’s stock valued at $3,818,000 after buying an additional 398 shares during the period. 92.73% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply